First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicentre phase II trial (SAKK 50/07)

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 531-536

  Von Moos, R ^a   Seifert, B ^b   Simcock, M ^c   Goldinger, S M ^d   Gillessen, S ^e   Ochsenbein, A ^f   Michielin, O ^g   Cathomas, R ^a   Schlappi M ^e   Moch, H ^d   Schraml, P H ^d   Mjhic Probst, D ^d   Mamot, C ^h   Schonewolf N ^d   Dummer, R ^d  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h Kantonal Hospital Aarau   (Switzerland)

Author keywords

Antiangiogenic therapy; Bevacizumab; First line treatment; Metastatic melanoma; Temozolomide

Indexed keywords

B RAF KINASE; BEVACIZUMAB; TEMOZOLOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER GRADING; CANCER STAGING; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEMALE; FRACTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TRISMUS; VOMITING; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84856363696     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr126     Document Type: Article

References (28)

1. Lin WM, Baker AC, Beroukhim R et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008; 68: 664-673.
2. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
3. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
4. Patel MP, Suciu S, Mortier L et al. Extended schedule escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized phase III study (EORTC 18032). Ann Oncol 2008 LBA 8.
5. Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21: 3351-3356.
6. Hwu WJ, Panageas KS, Menell JH et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 2006; 106: 2445-2451.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
8. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
9. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421-422.
10. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
11. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
12. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
13. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28): 4733-4740.
14. Brychtova S, Bezdekova M, Brychta T et al. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 2008; 55: 273-279.
15. Lev DC, Onn A, Melinkova VO et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004; 22: 2092-2100.
16. Liu B, Earl HM, Baban D et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995; 217: 721-727.
17. Danielsen T, Rofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer 1998; 76: 836-841.
18. Lacal PM, Ruffini F, Pagani E et al. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 2005; 27: 1625-1632.
19. Ugurel S, Rappl G, Tilgen W et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-583.
20. Terheyden P, Hofmann MA, Weininger M et al. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 2007; 133: 897-901.
21. Boasberg P, Cruickshank S, Hamid O et al. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 9061).
22. Gonzalez-Cao M, Viteri S, Diaz-Lagares A et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008; 74: 12-16.
23. O'Day SJ, Kim KB, Sosman JA et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Eur J Cancer 2009; 7(3): 13.
24. Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009; 115: 119-127.
25. Varker KA, Biber JE, Kefauver C et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14: 2367-2376.
26. Peyton JD, Spigel DR, Burriset HA et al. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: preliminary results. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 9027).
27. Newton CR, Graham A, Heptinstall LE et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-2516.
28. Benlloch S, Paya A, Alenda C et al. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006; 8: 540-543.